At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06660 AIM VACCINE
Not Yet Opened 12-12 16:08:07
3.510
+0.140
+4.15%
High3.540
Low3.370
Vol556.40K
Open3.370
D1 Closing3.370
Amplitude5.04%
Mkt Cap4.31B
Tradable Cap1.78B
Total Shares1.23B
T/O1.94M
T/O Rate0.11%
Tradable Shares507.67M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
AIM Vaccine Co., Ltd. (06660) Releases Monthly Return on Movements in Securities for November 2025
Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast
AIM Vaccine Co Ltd is a China-based company principally engaged in the research and development, manufacturing and sales of vaccine. The Company's products mainly include recombinant hepatitis B vaccine, human rabies vaccine, inactivated hepatitis A vaccine, mumps vaccine, inactivated hemorrhagic fever with renal syndrome vaccine and MPSV4. The Company's products are mainly used for the treatment of hepatitis B, hepatitis A, mumps, hemorrhagic fever with renal syndrome, rabies and meningococcal diseases. The Company's vaccine candidates include messenger RNA (mRNA) corona virus disease 2019 (COVID-19) vaccine, inactivated COVID-19 vaccine, broad-spectrum COVID-19 vaccine, PCV13, PPSV23 and MCV4. The Company principally conducts its businesses in the domestic market.